Articles tagged with Biopsies
Researchers will develop a molecular diagnostic test that quantifies small RNA species to detect fetal oxygen deprivation during labor. The technology aims to provide clinically relevant values for stratifying the risk of babies during labor.
A new study develops methods for clinicians to assess patient risk and builds an understanding of HFpEF's mechanisms, which could lead to new treatments. Researchers found potential mechanistic and molecular changes contributing to the condition.
Researchers found that people with well-controlled HIV have more fibrosis in their fat tissues, leading to insulin resistance and type 2 diabetes. The study also identified a blood marker of scarred fat, which may help predict metabolic future for individuals with HIV.
Liquid biopsy targeting viral ctDNA holds promise as a diagnostic and surveillance tool for head and neck cancer. The study aims to monitor treatment response and assess minimal residual disease (MRD) to adapt treatment via precision oncology.
Researchers found that patients often wait an average of four weeks for biomarker test results, with the first step taking up to 23 days to order testing. This delay can lead to mismatched therapies, toxic side effects, and reduced treatment options, emphasizing the need for improved testing turnaround times.
Researchers used an open-source AI model called Mirai to quickly identify high-risk patients and expedite their diagnostic process. This led to a significant reduction in wait times, with some women receiving biopsy results within days of having their mammograms done.
Researchers at Aalto University developed a new ultrasonic needle that can collect 2-3 times more tissue than current biopsy methods, improving cancer diagnosis accuracy. The minimally invasive approach shows strong potential for broader diagnostic use, particularly in rare salivary gland tumors.
A novel method for monitoring on-treatment disease burden in high-grade serous ovarian cancer uses tumor-informed breakpoints-spanning ddPCR, detecting superior sensitivity and specificity compared to real-time PCR. The approach may enable sensitive and specific detection of minimal residual disease and early relapse detection.
Researchers developed a computational tool that infers telomere length from structural changes in cells and tissues captured in medical biopsies. The TLPath model accurately predicts telomere length, providing new opportunities for studying human aging.
Research presented at EAU26 confirms that prostate cancer screening leads to a reduction in mortality, but also detects cancers that would otherwise remain undetected. The study's findings suggest that using MRI in prostate cancer screening can reduce overdiagnosis and unnecessary biopsies.
New research warns that popular AI systems for predicting cancer biology may rely on visual shortcuts, raising concerns about their reliability for real-world patient care. Despite achieving high accuracy, these models often fail when conditions change or confounding factors are controlled.
A new AI-powered algorithm, M-PACT, uses liquid biopsy to classify pediatric brain tumors based on DNA methylation patterns. The technology has been shown to achieve a high sensitivity rate of 92% in identifying brain tumors.
A new imaging technique using ultrasound-guided diffuse optical tomography can reduce unnecessary benign breast biopsies by nearly 25%, according to a recent study. The technology uses near-infrared light to create 3D pictures of tissues, revealing functional differences between normal and cancerous tissue.
A new liquid biopsy technology, Bridge Capture, has been developed to overcome the challenges of sensitive and cost-efficient cancer diagnostics. It detects rare variant allele frequencies with superior sensitivity compared to existing methods.
A study published in Molecular Oncology developed a liquid biopsy panel that can detect specific gene mutations in lung cancer patients, offering a potential solution for early detection and guiding patient treatment. The test showed promising results, detecting mutations in 65.6% of samples, including those in frozen samples without s...
A liquid biopsy test may enable early detection of various cancers, increasing stage I–III diagnoses by 10-30% and stage IV diagnoses by 45%. This could improve patient outcomes and reduce the economic impact of cancer. The study's findings suggest a game-changing approach to cancer control.
A new study found that one in six men with low-grade prostate cancer (GG1) actually have intermediate- or high-risk cancer when other clinical features are considered. This suggests that relying on biopsy grade alone can lead to underestimating disease risk and misclassifying individuals who may benefit from definitive treatment.
Researchers at UChicago have developed a more sensitive liquid biopsy test that uses RNA to detect the earliest stages of colorectal cancer with 95% accuracy. The test analyzes RNA modification levels in blood samples, which remain stable regardless of sample preparation.
A large clinical trial found that switching to an experimental drug after liquid biopsy detection of treatment-resistant mutations in breast cancer patients substantially extends tumor control and overall health status. The study, conducted at Weill Cornell Medicine, showed better outcomes compared to standard care.
A new $4 million grant will test whether Prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) Computed Tomography (CT) can improve prostate cancer monitoring while reducing screening-related harms. The study aims to reduce the need for biopsies in men with low- or intermediate-risk prostate cancers.
The ROME trial found that patients with concordant biopsy findings experienced improved survival outcomes when receiving tailored therapy based on genomic alterations detected in both tissue and liquid biopsies. This approach led to better overall survival, progression-free survival, and objective response rates compared to standard-of...
New molecular testing methods are transforming post-transplant care by detecting potential heart injury or rejection earlier than traditional biopsies. This enables physicians to reduce immunosuppressive medicine dosage in low-risk patients, potentially improving patient outcomes beyond the first year post-heart transplant.
Liquid biopsy analyzes circulating tumor components in body fluids to detect cancer at early stages, offering a safer and more dynamic alternative to traditional tissue biopsies. This non-invasive approach has shown promise in detecting various types of cancer, including lung, breast, colorectal, prostate, and gastric cancers.
The study directly compared Droplet-based scRNA (D-scRNA) and Picowell-based scRNA (P-scRNA) platforms for analyzing human mucosal biopsies. D-scRNA provides more detailed insights, but requires resources and may introduce contamination. P-scRNA is gentler, more resource-efficient, but less effective in capturing rare cell types.
Researchers developed a tiny magnetic robot that can take 3D scans from deep within the body, enabling 'virtual biopsies' for non-invasive cancer diagnosis and treatment. The device uses high-frequency imaging to create detailed 3D reconstructions, allowing clinicians to diagnose and treat colorectal cancer in a single procedure.
Patients with hormone receptor-positive and HER2-negative breast cancers face a higher risk of death from the cancer if they wait more than 42 days after diagnosis to have surgery. Delayed surgery increases the patient's risk exponentially, with risks of death increasing by 21%, 79%, and 183% at 60, 90, and 120 days, respectively.
A new study has shown that high-resolution ultrasound can diagnose prostate cancer as effectively as MRI, with improved resolution and lower costs. The technology, called micro-ultrasound, is expected to speed up diagnosis, reduce hospital visits, and make imaging more accessible, particularly in less developed healthcare systems.
Researchers from CNRS found that applying a mixture of sunscreen and insect repellent simultaneously decreases UV protection. The study used skin biopsies and computer tool analysis to measure the stress response of skin cells to radiation.
A study found significant racial disparities in who received same-day diagnostic services and biopsies after abnormal mammogram findings, with Black women being less likely to receive same-day biopsies. Rural-resident patients were more likely to receive same-day diagnostic services than urban residents.
A study found racial and ethnic minorities are less likely to receive standard-of-care diagnostic imaging after abnormal screening mammograms compared to white patients. Minority groups were also less likely to have access to same-day biopsy services, despite similar availability of most diagnostic services.
A new blood test using cell-free DNA from the placenta during pregnancy can predict preterm preeclampsia with 80% accuracy. The test's development is a significant breakthrough in prenatal care, potentially improving treatment outcomes for high-risk pregnancies.
A new technique using optical coherence tomography (OCT) probe aims to improve kidney biopsy imaging, reducing failed surgeries and improving patient outcomes. The technology could also help identify tumor types and reduce cases of renal hemorrhage.
Researchers have clinically validated a urine test that can detect aggressive prostate cancer, potentially avoiding unnecessary biopsies and overtreatment. The test, called MyProstateScore 2.0, analyzes 18 genes linked to high-grade prostate cancer and showed a 94% sensitivity rate.
Researchers will analyze tissue samples from 100 patients over three years to understand why some respond better than others to biologic and targeted therapies. The study aims to improve matching of treatments to individual patients, reducing the guesswork and cost associated with ineffective treatment.
A new blood test reveals heart transplant patients at risk of rejection by analyzing DNA fragments in their blood. This non-invasive test is comparable to existing US tests and could save millions in public healthcare costs.
A new study from the University of Texas M. D. Anderson Cancer Center found that at least 3% of normal breast tissue cells in healthy women contain chromosome abnormalities associated with invasive breast cancer, which may guide future approaches to early detection.
A new study found that a remote telemedicine tool called SpotCheck is highly accurate in diagnosing melanoma, with experts able to remotely examine skin lesions using dermoscopy. The tool has the potential to address diagnostic and treatment disparities for lower-income populations with limited access to dermatologists.
A Chinese Medical Journal study reveals that patients with prostate cancer can undergo surgical removal without a pre-operative biopsy, using a combination of mpMRI and PSMA PET/CT imaging. This approach reduces costs and complications associated with traditional biopsy methods.
Acute interstitial nephritis (AIN) is a common cause of acute kidney injury, often linked to medication use. Johns Hopkins researchers developed an electronic diagnostic model using machine learning to predict AIN in patients, showing improved accuracy in diagnosis and potential benefits for treatment decisions.
Researchers have developed a new protocol to exclusively access and quantify proteins carried by extracellular vesicles in the blood. This breakthrough may lead to early diagnosis of Parkinson's disease and other brain disorders, providing treatment opportunities before symptoms appear.
Researchers have developed a new tool that collects and analyzes extracellular vesicles to detect cancer cells more accurately. The digital approach allows for simultaneous analysis of multiple biomarkers, enabling earlier detection of cancer at curable stages.
Researchers developed a method to assess which patients with metastatic triple-negative breast cancer can benefit from immunotherapy. The tool uses predictive biomarkers and machine learning-based approaches to identify patients who are likely to respond to treatment.
Aston University researcher has developed a new technique harnessing Orbital Angular Momentum (OAM) light to improve imaging and data transmission through skin and biological tissues. The OAM-based approach shows unmatched sensitivity and accuracy, paving the way for non-invasive medical diagnostics and imaging.
Researchers at Tampere University have developed a non-electric touchpad that can sense force, area, and location of contact without electricity. The device is made of soft silicone and contains 32 channels, enabling precise detection of handwritten letters and multiple simultaneous touches.
A non-invasive blood test measuring circulating tumor cells can predict treatment response, disease progression, and overall survival in men with metastatic prostate cancer. Patients with more CTCs had shorter median survival lengths and a greater risk of death.
Researchers have developed an AI technology that can analyze mammary tissue biopsies to identify signs of damaged cells, a key indicator of breast cancer risk. The study found the AI was far better at predicting risk than current clinical benchmarks, offering improved treatment options for women.
A new prostate biopsy technique, transperineal biopsy, has been shown to lower the risk of infection compared to traditional biopsies. The PREVENT trial found no infections among men who underwent the transperineal procedure, while those with traditional transrectal biopsies had a 1.6% infection rate despite receiving antibiotics.
A new blood-based assay has been developed to detect IDH1.R132H-mutant gliomas with a high sensitivity of 75.0% and specificity of 88.7%. This minimally invasive test can monitor disease progression and response to treatment without the need for a biopsy.
Scalable telehealth mindfulness-based interventions show promise in treating chronic pain by improving function and reducing symptoms. The low-resource approach could accelerate the adoption of nonpharmacological pain treatment in healthcare systems.
A new AI protocol called DeepHRD enables accurate, instantaneous detection of cancer genomic biomarkers directly from tumor biopsy slides. This breakthrough technology saves weeks and thousands of dollars from clinical oncology treatment workflows, providing access and equity in cancer care for resource-constrained settings.
A new study sheds light on fatty liver disease MASH's pathology, revealing T cell activation and growth in response to poor diet. The research holds promise for developing a biomarker test to track disease progression before it's at a late stage.
Researchers at the University of Melbourne have developed a compact, high-efficiency metasurface-enabled solenoid beam that can draw particles toward it. The technology has the potential to reduce pain and trauma associated with current biopsy methods.
Researchers developed an electronic health record nudge to remind surgeons about the risks of lymphedema and potential overtreatment. The intervention led to a 49.3% reduction in sentinel lymph node biopsy procedures among eligible patients.
Researchers found that out-of-pocket costs for additional tests, including MRI and biopsies, are common and increasing among privately insured men with high PSA results. The median cost rose substantially between 2010-2020, deterring patients from undergoing recommended screening.
Researchers developed a novel liquid biopsy technique to monitor disease evolution in metastatic prostate cancer patients. The method analyzes DNA and RNA in circulating extracellular vesicles, capturing tumor genomics and transcriptomic changes.
A new liquid biopsy method analyzes gene fragments in the bloodstream to detect and track cancer, enabling oncologists to tailor treatment approaches to individual patients. This non-invasive test can help monitor treatment success, detect cancer recurrence, and improve patient quality of life.
Researchers at Weill Cornell Medicine have identified cellular and molecular markers that can predict when pancreatic cancer will spread to the liver or other organs. The study found that patients with early-stage pancreatic cancer who showed signs of immune exhaustion were more likely to develop liver metastases.
Researchers discuss primary hepatic angiosarcoma, a rare mesenchymal liver tumor, and its poor prognosis compared to hepatocellular carcinoma. Diagnosing PHA is critical due to its similar clinical presentation to HCC.
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
Researchers demonstrate the utility of analysing circulating tumor DNA (ctDNA) through a high-sensitivity liquid biopsy platform, allowing for early prediction of treatment response and prognosis. The study shows that detecting low levels of ctDNA can predict longer progression-free survival and overall survival.